Comparison 6. Atovaquone‐proguanil (AP) versus mefloquine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment failure on or by day 28	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Parasite clearance time (mean; h)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 Fever clearance time (mean; h)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 Adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Abdominal pain	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Anaemia	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 Diarrhoea	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.4 Dizziness	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.5 Headache	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.6 Insomnia	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.7 Nausea	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.8 Raised liver enzymes	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.9 Sore throat	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.10 Vomiting	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.11 Any event	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]